摘要
猪链球菌(Streptocuccus suis,S.suis)是当前严重危害养猪业的一种重要病原菌。根据荚膜多糖(capsular polysaccharide,CPS)抗原成分不同,将猪链球菌分为35个血清型(1-34型和1/2型)。其中,猪链球菌2型(Streptococcus suis serotype 2,SS2)是最常见、也是毒力最强的血清型,同时也是一种重要的人兽共患病原菌。
猪链球菌2型revS基因是一种反应调控因子(response regulator),在SS2致病过程中可能起着很重要的作用。研究发现该基因能够在转录水平上对SS2多种毒力因子进行调控,缺失该基因后多种毒力因子表达减弱。鉴于此,本研究构建了猪链球菌2型revS基因缺失菌株和质粒介导的互补菌株,并对缺失菌株和互补菌株的生物学特性进行了研究,进一步研究其所调控毒力因子的表达情况,为深入研究猪链球菌2型的的分子致病机理奠定前期基础。
透明质酸酶(hyaluronidase,HYL)由猪链球菌2型Hyt基因编码,该酶为粘多糖分解酶,可水解组织基质中的透明质酸,增加组织的通透性。另外也有研究报道,HYL可以作为一种调控蛋白,通过降低血中的透明质酸酶的浓来诱导血管的增生。在SS2感染过程中,细菌分泌的透明质酸酶是否可以改变宿主细胞通透性,导致链球菌及其分泌的毒力因子更容易进入宿主细胞内而发挥毒性作用有关目前还不清楚。因此,本研究利用酵母双杂交技术,以透明质酸酶作为诱饵蛋白,从小鼠的脑细胞和人的肺细胞cDNA文库中寻找HYL的互作蛋白,旨在为进一步探索HYL在SS2致病中的作用提供理论依据。
鉴于以上研究背景,本研究主要开展了以下研究内容:
1.猪链球菌2型revS基因缺失菌株和互补菌株的构建与鉴定
通过PCR分别扩增了revS基因上下游同源臂p1和p2基因片段、开放阅读框(ORF)和全长序列,利用温度敏感型“自杀性”质粒pSET4s构建了质粒pSET4s-p1-p2,并将该重组质粒电转化进入亲本菌SS2野生菌株SC21中,通过抗生素和温度双重标记筛选,获得revS基因缺失菌株,命名SC211。另外,将revS全长基因定向插入穿梭载体pAT18中,构建了穿梭质粒pAT18-revS,并将该质粒电转入revS基因缺失菌株SC211,通过抗生素筛选,得到质粒介导的revS基因互补菌株,命名为SC212。通过PCR、Southern blotting进一步对基因缺失突变菌株和互补菌株进行了鉴定,证实构建正确。
2.猪链球菌2型revS基因缺失菌株和互补菌株的生物学特性研究
通过细菌传代培养,对缺失突变菌株SC211和互补菌株SC212的遗传稳定性进行了分析,结果显示缺失突变菌株和互补菌株能够稳定生长。比较了基因缺失突变菌株、互补菌株及野生菌株的生长特性,发现缺失菌株的生长速度明显加快,互补菌株也比野毒菌株的生长快。溶血性试验结果表明,基因缺失后SC211的溶血活性明显降低,而互补菌株SC212的溶血活性虽然有所回复,比基因缺失菌株明显提高,但是没有达到野毒菌株的水平。利用Hep2细胞为模型,研究不同菌株对细胞黏附特性,结果显示,基因缺失后链球菌对Hep2细胞的黏附能力明显下降,只有野毒菌株的29%:互补菌株虽然黏附能力比基因缺失菌株要高,但是没有达到野毒菌株的水平,只有野毒菌株的79%。以CD1小鼠为模型比较了不同菌株的毒力,结果显示基因缺失后链球菌毒力明显下降,基因缺失菌株的LD_(50)(7.78×10~7)是野毒菌株LD_(50)(7.63×10~6)的10倍,而互补菌株的毒力有所增高,但是没有达到野毒菌株的水平,其LD_(50)(2.44×10~7)是野毒菌株的3倍。
3.猪链球菌2型revS基因缺失菌株和互补菌株的毒力相关因子的相对定量分析
利用定量PCR研究了SS2毒力相关因子体内外表达情况。体外定量结果显示:除了cps和gapdh外,基因缺失菌株其他的毒力相关因子(ef,fops,hyt,sly,sod,mrp,gyrap,和rpob)的表达都要比野毒菌株低,其中ef,fbps,hyl,sly和mrp约下降了50%—80%。而互补菌株在gyrap、rpob和gapdh的表达上和野毒菌株没有明显差别,其他毒力因子(cps,ef,fbps,hyl,sod,sly和mrp)的表达都明显增高,在一定程度上上调了0.5—1.5倍。
攻毒后不同时间SS2毒力相关因子的表达水平比较发现:攻毒48h后的组织中链球菌毒力相关因子的表达量要比攻毒24h和72h的高,但是差异不显著。而攻毒后不同组织中的SS2毒力相关因子的表达水平比较发现:攻毒后组织中毒力相关因子的表达量都比体外的高,差异显著(p＜0.01%)。脑组织和肺组织中链球菌毒力相关因子的表达水平比血中的高,但是差异不显著。在体内,不同菌株毒力相关因子的表达水平比较发现:在体内cps的表达野毒菌株和基因缺失菌株之间没有明显差异,但互补菌株的cps表达量是野毒菌株和基因缺失菌株的1.2倍。在基因缺失菌株中,mrp,ef,sly,fbps,sod,rpob,gyra和hyl的表达量分别比野毒菌株降低了41%,37%,29%,39%,33%,46%,36%和49%,而在互补菌株中这些毒力相关因子的表达量比基因缺失菌株增高了1.5—2.5倍,而不同组织中gapdh的表达没有差异。
4.猪链球菌2型revS基因缺失菌株和互补菌株的免疫原性的研究
免疫保护性实验结果表明:10~6cfu的基因缺失菌株免疫CD1小鼠后能够对猪链球菌2型野毒菌株的攻击提供90%免疫保护,10~7cfu的基因缺失菌株免疫CD1小鼠后能够对猪链球菌2型野毒菌株的攻击提供100%免疫保护力;10~5cfu的互补菌株免疫CD1小鼠后能够对猪链球菌2型野毒菌株的攻击提供90%免疫保护力,10~6cfu的互补菌株免疫CD1小鼠后能够对猪链球菌2型野毒菌株的攻击提供100%免疫保护力。不同菌株免疫CD1小鼠后ELISA抗体水平测定结果显示:revS基因缺失后,猪链球菌2型的免疫原性并没有太大的变化,基因缺失菌株免疫后所诱导的cps抗体水平与野毒菌株差异不显著,但互补菌株的cps抗体水平明显高于野毒菌株和基因缺失菌株。
5.猪链球菌2型HYL蛋白与宿主互作蛋白的筛?
通过PCR方法扩增SS2 Hyl全长基因,定向克隆到pSos载体中,构建bait载体(pSos-Hyl)。将pSos-Hyl分别与鼠脑和人肺cDNA文库(pMyr-cDNA)共转化cdc25H酵母细胞,筛选与HYL相互作用的阳性克隆。经过筛选和重复验证,并对所得到的Target载体插入片段进行测序,BLAST分析,从鼠的脑组织cDNA文库中得到2个与HYL相互作用的阳性克隆,两个基因分别与锌指结构基序(widely-interspaced zinc fingermotifs gene of Mus musculus(NT-039649 REGION:18685755..18718324),WIZF)和血管生长因子抑制因子1(ribonuclease/angiogenin inhibitor 1 gene of Mus musculus(NT-166306 REGION:2098219..2104509),AI1)基因的同源性为99%和100%;从人的肺组织cDNA文库中得到2个与HYL相互作用的阳性克隆,两个基因分别与γ内收蛋白(Homo sapiens adducin 3(gamma)(NT_030059.12),ADD3)和装配架离子转运蛋白(Homo sapiens chromosome 6genomic contig,reference assembly,ion transporter protein(NT_034880.3),AITP)基因的同源性为99%和100%。
6.猪链球菌2型HYL蛋白与宿主互作蛋白的验证与分析
将Hyl克隆到pET-28c载体中,构建重组表达载体(pET28c-Hyl)进行原核表达,同时将筛选得到的WIZF、AI1、ADD3和AITP基因分别进行真核细胞表达后,用免疫共沉淀试验验证了HYL与AI1、ADD3和MTP之间的相互作用,而HYL与WIZF的证实没有发生相互作用。进一步并分析和预测了AI1、ADD3和AITP可能与SS2致病性的关系。血管上皮细胞生长抑制因子(AI1)主要是抑制血管上皮细胞的生长,从而导致血管的通透性的改变,利于细菌的扩散。而ADD3是一种内收蛋白,也是一种细胞膜骨架蛋白,内收蛋白的确切功能尚不明了,但是已知它与细胞膜表面spectrin和肌动蛋白连接部位的定向组装信号传导和跨膜离了转运有关,它的改变可以导致细胞膜的通透性的改变。AITP是一种离子转运蛋白,是细胞内外离子转运的载体,与细胞膜的离子通道和通透性有关。
Streptococcus suis(S.suis) is a common pathogenic microorganism and can cause a variety of clinical diseases in human and swine.Based on the CPS antigens of S.suis,35 serotypes or capsular types have been characterized.S.suis serotype 2(SS2) is most commonly and most virulent of these serotypes.
revS gene is the response regulator gene of SS2,belonging to a two component system,which can affect the virulence gene expression of streptococcus suis.For further research the virulence gene expression regulated by revS,revS gene mutant strain and reversible mutant strain were constructed and characteristic analyzed.
Hyaluronidase is a kind of protein coding by Hyl gene of SS2,it is mueopolysaccharide lytic enzyme which can hydrolyze the hyaluronic acid of periplast, result in the permeability of the tissue augmentation.In addition some research report HYL can act as a modulin,density of HYL in the blood is descended which can induce Blood vessel accrementition.In the course of SS2 infection,whether the hyaluronidase secreted by SS2 can result in the permeability of the tissue augmentation,ease to the ingress of virulence factors secreted by SS2 into the host and play effect is not clear.So in the research hyaluronidase was used as a bait protein to search its interacted protein from Mouse brain cDNA library and human lung cDNA library using the yeast two hybrid system to explore its function in SS2 infection.So the following researches were explored.
1.Construction and verification of SS2 revS gene mutant strain and complementation strain
In the research two DNA fragments flanking the revS gene were amplified by PCR from the genome of S.suis 2 SC21.The fragments of the N-terminus and the C terminus flanking region of the revS gene were digested with BamH I/SalⅠand Sal I/EcoRⅠ, respectively.The revS-flanking PCR products were mixed in equal amounts and inserted directly into BamH I/EcoRⅠdigested and dephosphorylated thermosensitive suicide vector pSET4s,ligated,and transformed into E.coli DH5α.The resulting plasmid, pST4S-revS,was electroporated into S.suis 2 SC21,and the resultant strains were grown at 28℃in the presence of spectinomycin(100μg/mL) selection and subsequently passaged at 37℃in the absence of spectinomycin selection as described previously. Successful deletion of the gene revS was confirmed by PCR and Southern blotting. Southern blotting analysis confirmed the successful deletion of the revS gene in the chromosome of the S.suis 2 revS gene mutant strain named SC211.In addition complementation strain was constructed too.The revS structural gene,including its own promoter,was amplified from chromosomal DNA S.suis 2 SC21 by PCR.The PCR product was cut with Sal I/BamHⅠand ligated into the Sal I/BamHⅠdigested E. coli/Streptococcus shuttle vector pAT18(Trieu-Cuot P et al.1991).The resultant plasmid was termed pAT18-revS.The plasmid pAT18-revS were transformed by electroporation into the revS gene mutant strain with subsequent erythromycin selection. Complementation strain designed SC212.The mutant strain and complementation strain were confirmed by PCR and Southern blotting.
2.Bionomics research of the mutant strain and complementation strain
The results of the growth curve of the mutant strain、complementation strain and wide type strain show that the mutant strain and complementation strain grow faster than that of wide type strain.The hemolytic activity of wild-type strain was three times higher than that of mutant strain.The hemolytic activity of complementation strain was restored, and was about two times higher than mutant strain SC211.but it did not reach the level of wild-type strain.Reduction of 79%in the adherence to the Hep2 cell of mutant strain compared with wild-type.The adherence of complementation strain was about three times that of mutant strain,but only 81%of the wild-type strain.LD50 values were 7.63×10~6 CFU per mouse for wild-type strain,7.78×10~7 CFU per mouse for mutant strain,and 2.44×10~7 CFU per mouse for complementation strain.Compared with parent strain, mutant strain was attenuated at least ten fold.Complementation strain was restored three fold than the mutant strain.
3.Immunogenic research of the mutant strain and complementation strain
A vaccine dose of 10~7 CFU mutant strain and 10~6 CFU complementation strain was protective against an extremely high challenge dose of 4×10~7 CFU.These results demonstrated that the Streptococcus suis-2 revS gene mutant was highly attenuated in the mouse model,and 100%protective against homologous bacterial challenge at 10~7 CFU vaccine-challenge doses.The complementation strain was attenuated in the mouse model, and was 100%protective against homologous bacterial challenge at 10~6 CFU vaccine-challenge doses.The ELISA antibody level of mutant strain has no difference with wide type strain,but the ELISA antibody level of the complementation is higher than that of mutant strain and wide type strain.
4.Relative quantitative PCR assay of virulence associated gene of SS2
The characteristic of SC211 and SC212 were researched further.The virulence of different strains were determined by animal infection,the virulence is decreased clearly when the revS gene knocked out,the virulence is reverted when the revS gene reverted, but which can not get to the level of the wide type.Many virulence associated genes, including mrp,ef,sly,fbps,sod,rpob,gyra and hyl,are shown to be effeeted by revS gene, the expression level decreased obviously when revS gene knocked out,but the cps and gapdh is not effected by revS,the virulence gene expression of the reversible mutant were exceeded the wide type.In this study,the differential expression of the key S.suis serotype 2 virulence-associated genes of different strains was further investigated in bacteria harvested from the blood,lungs and brains of mice 24,48,and 72h post intraperitoneal infection with different strain S.suis.Bacterial RNA was extracted and gene expression was monitored using real-time reverse transcriptase-PCR at various time points.In all organs the expression level of wide type strain is higher than mutant strain at all time,the reversible mutant strain were higher than the other two strains,the virulence gene expression were similar to that observed in vitro,while the expression level in vivo were higher than their in vitro levels.But at different time the difference of same virulence gene expression between in vivo and in vitro is changed.With the time of infection delay the difference of same virulence gene expression between reversible mutant strain and wide type strain or mutant strain is contracted.In vivo the cps expression was changed obviously.At all the time postinfection,all genes examined were higher than their in vitro levels in the blood,lungs and brains,revS gene can affect the virulence associated gene expression and contribute to S.suis pathogenesis.
5.Screen of the interaction protein of HYL of SS2
The full length Hyl gene was amplified from chromosomal DNA of SS2 strain SC21 by PCR,Hly gene was directional cloned into pSos vector after the amplified PCR product and pSos vector were digested with BamHⅠand SalⅠ,yielding the bait plasmid pSos-Hyl.The recombinant expression plasmid pET-28c-Hyl was constructed by the same way at the same time.The library was screened by co-transformation of the pSos-Hyl bait constructed into a temperature- sensitive cdc25H yeast strain that can not grow at 37℃. If the bait protein physically interacts with the target protein,the hSos protein is recruited to the membrane activating the Ras signaling pathway and allowing the cdc25H yeast strain to grow at 37℃.The clones growing at 37℃on SD/galactose(-UL) plates but not on SD/glucose(-UL) plates were selected as "putative positive" clones and were analyzed further.The Target plasmid DNA was isolated from pMyr-cDNA putative positive clones and was transformed into E.coli cells for plasmid amplification.Colonies contains cDNA fragment insertion identified by restriction digest analysis.The positive Target plasmid was sequenced on a 3730 Sequencing system.The sequencing results were sent to NCBI for BLAST searches on line.In this study two positive target plasmid received from the Mouse brain cDNA library.One of these genes is identical to the widely-interspaced zinc finger motifs gene of Mus museulus(WIZF).The other showed homology to ribonuclease/angiogenin inhibitor 1 gene of Mus musculus(AI1).At the same time two positive target plasmid received from the human lung cDNA library.One of these genes is identical to Homo sapiens adducin 3 gene(ADD3).The other showed homology to assembly ion transporter protein gene of homosapiens(AITP).
6.Confirmation of the protein-protein interaction between HYL and targets received
The protein-protein interaction between HYL and targets received was confirmed by ProFound Co-immunoprecipation assay.Recombinant plasmid pET-28c-Hyl was transformed into E.coli BL21 cells for protein expression.The coding sequence of WIZF、AI1,ADD3 and AITP obtained by PCR from the target vectors respectively,then they were subcloned into pcDNA3.1/myc-His,yielding four recombinant expression plasmids.The recombinant expression plasmids were transfected into 293T cells for protein expression.Anti-myc probe antibody was used to immunoprecipitate the expressed protein(WIZF、AI1、ADD3 or AITP) from the whole cell lysate and supernatant of BL21 transformed with pET-28c-Hyl culture.The complex was then resolved on a 10%SDS polyacrylamide gel.The separated proteins were transferred to a nitrocellulose membrane.Pig anti-sera against SS2 were used for western-blotting.But the interaction between HYL and WIZF were not confirmed by this way.The relation between the function of AI1、ADD3 or AITP and the pathopoiesis was analyzed.AI1 can inhibit the growth of blood vessel cellula epithelialis,which result in the permeability of the blood vessel changed ease to the diffuse of SS2.ADD3 is a kind of adducing,cell membrane skeleton protein.AITP is ion transporter protein of the cell membrane.These two protein belongs to the ion channel of the cell membrane,which is associated with the permeability of the cell membrane.
引文
1 曹三杰,段丽丽,肖驰,文心田.猪2型链球菌毒力因子研究进展.[J]中国人兽共患病学报,2007,23:89-91.
2 何孔旺,倪艳秀,王继春,何家惠,王伟峰,杨瑛,陆承平,林继煌.猪链球菌2型的分子流行病学研究.[J]中国人畜共患病杂志,2002,18:45-47.
3 胡又佳,高枫,朱春宁等.PEG/LiAc转化酵母细胞方法的改进.[J]生物技术.1998,8(5):22.
4 江毅,仟国胜,石远,王小毅.透明质酸酶与血管内皮生长因子在人乳腺癌侵袭与转移中的作用.[J]肿瘤研究与临床.2005,17(2):80-82.
5 林存刚,徐慧等.酵母双杂交系统研究及其应用发展,[J]微生物学杂志,2005,25(6):85-89.
6 曲蕾,姬胜利.透明质酸及透明质酸酶与肿瘤的关系[J].中国生化药物杂志,200728(2):127.129
7 汪毅,任国胜.透明质酸酶及其在恶性肿瘤的转移与浸润中的作用.[J]实用肿瘤学杂志.2005,19(2):155-158.
8 王敬旭,廖贵清.透明质酸及透明质酸酶在肿瘤生长和转移中作用的研究进展.[J]国外医学口腔医学分册.2004,31(6):421-423.
9 王咏梅,吴宗贵,李莉,张玲珍,仲人前.透明质酸酶和透明质酸对血管内皮细胞增殖及CD44表达的影响.[J]第二军医大学学报.2001,22(2):144-147.
10 曾巧英,陆承平.猪链球菌2型溶菌酶释放蛋白诱导上皮细胞融合和凋亡.[J]微生物学报,2003,43:407-412.
11 Aarestrup FM,Jorsal SE,Jensen NE.Serological characterization and antimicrobial susceptibility of Streptococcus suis isolates from diagnostic samples in Denmark during 1995 and 1996.Vet Microbiol,1998a,60:59-66.
12 Aarestrup FM,Rasmussen SR,Artursson K,Jensen NE.Trends in the resistance to antimicrobial agents of Streptococcus suis isolates from Denmark and Sweden.Vet Microbiol,1998b,63:71-80.
13 Akhtar,M.S.,and V.Bhakuni.2003.Streptococcus pneumoniae hyaluronate lyase contains two non-cooperative independent folding/unfolding structural domains:characterization of functional domain and inhibitors of enzyme.J.Biol.Chem.278:25509-25516.
14 Allen AG;Bolitho S,Lindsay H,Khan S,Bryant C,Norton P,et al.Generation and characterization of a defined mutant of Streptococcus suis lacking suilysin.Infect Immun,2001,69:2732-2735.
15 Allen AG,Lindsay H,Seilly D,Bolitho A,teters SE,Maskell DJ.Identification and characterisation of hyaluronate lyase from Streptococcus suis. Microbial Pathogenesis, 2004, 36:327-335.
16 Allgaier A, Goethe R, Wisselink HJ, Smith HE, Valentin-Weigand P. Relatedness of Streptococcus suis Isolates of Various Serotypes and Clinical Backgrounds as Evaluated by Macrorestriction Analysis and Expression of Potential Virulence Traits, J Clin Microbiol, 2001, 39: 445-453.
17 Benga L, Goethe R, Beilage EG, Valentin-Weigand P. Immunogenicity of Murein-associated Proteins from Temperature-stressed Streptococcus suis Cultures. J Vet Med, 2004b, 51, 272-277.
18 Benga L, Goethe R, Rohde M, Valentin-Weigand P. Non-encapsulated strains reveal novel insights in invasion and survival of Streptococcus suis in epithelial cells. Cell Microbiol, 2004a, 6:867-881.
19 Bensaid T, Bonnefoi-Kyriacou B, Dupel-Pottier C, Bellon O, Lagier E, Chardon H. Streptococcus suis meningitis after wild boar hunting. Presse Med, 2003, 32:1077-1078.
20 Berry AM, Paton JC. Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun, 2000, 68:133-140.
21 Berthelot-Herault F, Gottschalk M, Morvan H, Kobisch M. Dilemma of virulence of Streptococcus suis: Canadian isolate 89-1591 characterized as a virulent strain using a standardized experimental model in pigs. Can J Vet Res, 2005, 69:236-240.
22 Berthelot-Herault F, Marois C, Gottschalk M, Kobisch M. Genetic diversity of Streptococcus suis strains isolated from pigs and humans as revealed by pulsed-field gel electrophoresis. J Clin Microbiol, 2002,40:615-619.
23 Berthelot-Herault F, Morvan H, Keribin AM, Gottschalk M, Kobisch M. Production of muramidase released protein (MRP), extracellular factor (EF) and haemolysin by field isolates of Streptococcus suis capsular type 2, 1/2, 9, 7 and 3 isolated from swine in France. Vet Res, 2000, 31:473-479.
24 Berthelot-Herault, F., R. Cariolet, A. Labbe, M. Gottschalk, J. Y. Cardinal, and M. Kobisch. 2001. Experimental infection of specific pathogen free piglets with French strains of Streptococcus suis capsular type 2. Can. J. Vet. Res. 65:196-200.
25 Billington SJ, Jost BH, Songer JG. Thiol-activated cytolysins: structure, function and role in pathogenesis. FEMS Microbiol Lett, 2000, 182:197-205.
26 Bohnsack, J. F., S. Takahashi, S. R. Detrick, L. R. Pelinka, L. L. Hammitt, A. A. Aly, A. A. Whiting, and E. E. Adderson. 2001. Phylogenetic classification of serotype III group B streptococci on the basis of hylB gene analysis and DNA sequences specific to restriction digest pattern type III-3. J. Infect. Dis. 183:1694-1697.
27 Bolken TC, Franke CA, Jones KF, Zeller GO, Jones CH, Dutton EK, Hruby DE. Inactivation of the srtA gene in Streptococcus gordonii inhibits cell wall anchoring of surface proteins and decreases in vitro and in vivo adhesion. Infect Immun, 2001, 69:75-80.
28 Bourguignon, L. Y., P. A. Singleton, F. Diedrich, R. Stern, and E. Gilad.2004. CD44 interaction with Na -H exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J. Biol. Chem. 279:26991-27007.
29 Brousseau R, Hill JE, Prefontaine G, Goh SH, Harel J, Hemmingsen SM. Streptococcus suis Serotypes Characterized by Analysis of Chaperonin 60 Gene Sequences. Appl Environ Mecrobiol, 2001, 67: 4828-4833.
30 Chabot-Roya G, Willsonb P, Seguraa M, Lacouturea S, Gottschalk M. Phagocytosis and killing of Streptococcus suis by porcine neutrophils. Microbial Pathogenesis, 2006,41:21-32.
31 Charland N, Harel J, Kobisch M, Lacasse S, Gottschalk M. Streptococcus suis serotype 2 mutants deficient in capsular expression. Microbiology, 1998, 144:325-332.
32 Charland N, Nizet V, Rubens CE, Kim KS, Lacouture S, Gottschalk M. Streptococcus suis serotype 2 interactions with human brain microvascular endothelial cells. Infect Immun, 2000, 68:637-643.
33 Chatellier S, Gottschalk M, Higgins R, Broussear R, Harel J. Relatedness of Streptococcus suis Serotype 2 Isolates from Different Geographic Origins as Evaluated by Molecular Fingerprinting and Phenotyping, J Clin Microbiol, 1999, 37:362-366.
34 Chatellier S, Harel J, Zhang Y, Gottschalk M, Higgins R, Devriese LA, Brousseau R. Phylogenetic diversity of Streptococcus suis strains of various serotypes as revealed by 16S rRNA gene sequence comparison. Int J Syst Bacteriol, 1998, 48: 581-589.
35 Clarise Rivera Starr1, N. Cary Engleberg. Role of Hyaluronidase in Subcutaneous Spread and Growth of Group A Streptococcus. Infect and immune, Jan. 2006, Vol. ,74, No. 1p. 40-48
36 Cloutier G, D'Allaire S, Martinez G, Surprenant C, Lacouture S, Gottschalk M. Epidemiology of Streptococcus suis serotype 5 infection in a pig herd with and without clinical disease. Vet Microbiol, 2003; 97:135-151.
37 Cohen J. The immunopathogenesis of sepsis. Nature, 2000, 420: 885-891.
38 Costa AT, Lobato FC, Abreu VL, Assis RA, Reis R, Uzal FA. Serotyping and evaluation of the virulence in mice of Streptococcus suis strains isolated from diseased pigs. Rev Inst Med Trop Sao Paulo, 2005, 47: 113-115
39 de Greeff A, Buys H, Verhaar R, Dijkstra J, van Alphen L, Smith HE. Contribution of Fibronectin-Binding Protein to Pathogenesis of Streptococcus suis Serotype 2. Infect Immun, 2002, 70:1319-1325.
40 de Greeff A, van Alphen L, Smith HE. Selection of Recombinant Antibodies Specific for Pathogenic Streptococcus suis by Subtractive Phage Display. Infect Immun, 2000, 68: 3949-3955.
41 Denchi EL, Helin K. E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep, 2005, 6: 661-668.
42 Didi Baev, Seung-Ho Ohk, Howard K. Kuramitsu. Protein interactions of SGP, an essential Streptococcus mutans GTPase, revealed by biochemical and yeast two-hybrid system analyses. FEMS Microbiology Letters, 2000, 184:149-153.
43 Dixon EP, Johnstone EM, Lin X, Little SB. An inverse mammalian two-hybrid system for beta secretase and other proteases. Anal Biochem, 1997,249:239-241.
44 Fan Z, Zhuo Y, Tan X, Zhou Z, Yuan J, Qiang B, Yan J, Peng X, Gao GF. SARS-CoV Nucleocapsid Protein Binds to hUbc9, a Ubiquitin Conjugating Enzyme of the Sumoylation System. J Med Virol, 2006, 78:1365-1373.
45 Fashena SJ, Serebriiskii I, Golemis EA. The continued evolution of two-hybrid screening approaches in yeast: how to outwit different preys with different baits. Gene, 2000, 250:1-14.
46 Francois B, Gissot V, Ploy MC, Vignon P. Recurrent Due to Streptococcus suis. J Clin Microbiol, 1998,36:2395.
47 Galina L, Vecht U, Wisselink HJ, Pijoan C. Prevalence of various phenotypes of Streptococcus suis isolated from swine in the U.S.A. based on the presence of muraminidase-released protein and extracellular factor. Can J Vet Res, 1996, 60:72-74.
48 Ghyslaine Vanier, Mariela Segura et al.Invasion of Porcine Brain Microvascular Endothelial Cells by Streptococcus suis Serotype 2. J Infect Immun. 2004 March; 72(3): 1441-1449.
49 Gottschalk M, Lebrun A, Wisselink H, Dubreuil JD, Smith H, Vecht U. Production of virulence-related proteins by Canadian strains of Streptococcus suis capsular type 2. Can J Vet Res, 1998; 62:75-79.
50 Gottschalk M, Segura M. The pathogenesis of the meningitis caused by Streptococcus suis: the unresolved questions. Vet Microbiol, 2000, 76:259-272.
51 Granlund M, Oberg L, Scum M, Norgren M. Identification of a novel insertion element, IS 1548, in group B streptococci, predominantly in strains causing endocarditis. J Infect Dis, 1998,177:967-976.
52 Grawunder U, Wilm M, Wu X, Kulesza P, Wilson TE, Mann M, Lieber MR. Activity of DNA ligase IU stimulated by complex formation with XRCC4 protein in mammalian cells. Nature, 1997, 388:492-495.
53 Gunther B, Ozegowski JH, Kohler W. Occurrence of extracellular hyaluronic acid and hyaluronate lyase in streptococci of groups A, B, C, and G Zentralbl Bakteriol, 1996,285:64-73.
54 Halbur PG, Thanawongnuwech R, Brown G, Kinyon J, Roth J, Thacker E, Thacker B. Efficacy of antimicrobial treatments and vaccination regimens for control of porcine reproductive and respiratory syndrome virus and Streptococcus suis coinfection of nursery pigs. J Clin Microbiol, 2000, 38:1156-1160.
55 Harel J, Martinez G, Nassar A, Dezfulian H, Labrie SJ, Brousseau R, Moineau S, Gottschalk M. Identification of an Inducible Bacteriophage in a Virulent Strain of Streptococcus suis Serotype 2. Infect Immun, 2003, 71:6104-6108.
56 Hassan AA, Khan IU, Abdulmawjood A, Lammler C. Inter- and intraspecies variations of the 16S-23S rDNA intergenic spacer region of various streptococcal species. Syst Appl Microbiol, 2003,26:97-103.
57 Heath PJ, Hunt BW. Streptococcus suis serotypes 3 to 28 associated with disease in pigs. Vet Rec, 2001,148:207-208.
58 Heidt MC, Mohamed W, Hain T, Vogt PR, Chakraborty T, Domann E. Human Infective Endocarditis Caused by Streptococcus suis Serotype 2. J Clin Microbiol, 2005,43:4898-4901.
59 Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev, 1998, 8:28-35.
60 Higgins R, Gottschalk M. Distribution of the Streptococcus suis capsular types in 1999. Can Vet J, 2000, 41:414.
61 Higgins, R.; Gottschalk, M. Streptococcal diseases. In: Leman A D, Straw B E, Mengeling W L, D'Allaire S, Taylor D J. , editors. Diseases of swine. 8th ed. Ames: Iowa State University Press; 1999. pp. 563-570
62 Hill JE, Gottschalk M, Brousseau R, Harel J, Hemmingsen SM, Goh SH. Biochemical analysis, cpn60 and 16S rDNA sequence data indicate that Streptococcus suis serotypes 32 and 34, isolated from pigs, are Streptococcus orisratti. Vet Microbiol, 2005, 107:63-69.
63 Homer K, Shain H, Beighton D. The role of hyaluronidase in growth of Streptococcus intermedius on hyaluronate. Adv Exp Med Biol, 1997, 418:681-683.
64 Hornish RE, Kotarski SF. Cephalosporins in veterinary medicine-Ceftiofur use in food animals. Curr Top Med Chem, 2002,2:717-731.
65 Hu X, Zhu F, Wang H, Chen S, Wang G Studies on human streptococcal infectious syndrome caused by infected pigs. Zhonghua Yu Fang Yi Xue Za Zhi, 2000, 34: 150-152.
66 Hua SB, Luo Y, Qiu M, Chan E, Zhou H, Zhu L. Construction of a modular yeast two-hybrid cDNA library from human EST clones for the human genome protein linkage map. Gene, 1998,215:143-152.
67 Huang J and Schreiber SL. A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. Proc Natl Acid Sci USA, 1997,94:13396-13401.
68 Huang SH, Stins MF, Kim KS. Bacterial penetration across the blood-brain barrier during the development of neonatal meningitis. Microbes Infect, 2000, 2:1237-1244.
69 Huang YT, Teng LJ, Ho SW, Hsueh PR. Streptococcus suis infection. J Microbiol Immunol Infect, 2005, 58:306-313.
70 Hynes WL, Walton SL. Hyaluronidases of Gram-positive bacteria. FEMS Microbiol Lett, 2000,183:201-207.
71 Hynes, W. L., and S. L. Walton. 2000. Hyaluronidases of gram-positive bacteria. FEMS Microbiol. Lett. 183:201-207.
72 Hynes, W. L., L. Hancock, and J. J. Ferretti. Analysis of a second bacteriophage hyaluronidase gene from Streptococcus pyogenes: evidence for a third hyaluronidase involved in extracellular enzymatic activity. Infect. Immun. 63:3015-3020.
73 Ito T, Chiba T, Ozawa R, Yoshida M, Hattori M, Sakaki Y. A comprehensive two-hybrid analysis to explore the yeast protein interactome. Proc Natl Acad Sci, 2001, 98: 4569-4574.
74 Jackson MW and Piano GV. Interactions between type III secretion apparatus components from Yersinia pestis detected using the yeast two-hybrid system. FEMS Microbiology Letters, 2000, 86:85-90.
75 Jacobs A A, Van Den Berg A J, Loeffen P L. Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis. Vet Rec. 1996; 139:225-228.
76 Joh D, Warm ERW, Kreikemeyer B, Speziale P, Hook M. Role of fibronectin-binding MSCRAMMS in bacterial adherence and entry into mammalian cells. Matrix Biol, 1999, 18:211-223.
77 Karimova G, Ladant D, Ullmann A. Two-hybrid systems and their usage in infection biology. Int J Med Microbiol, 2002,292:17-25.
78 Karimova G, Pidoux J, Ullmann A, Ladant D. A bacterial two-hybrid system based on a reconstituted signal transduction pathway. 1998, Proc Natl Acad Sci USA, 95:5752-5756.
79 Kataoka Y, Yoshida T, Sawada T. A 10-year survey of antimicrobial susceptibility of Streptococcus suis isolates from swine in Japan. J Vet Med Sci, 2000, 62:1053-1057.
80 Kim JW, Cho HS, Kim JH, Hur SY, Kim TE, Lee JM, Kim IK, Namkoong SE. AAC-11 overexpression induces invasion and protects cervical cancer cells from apoptosis. Lab Invest, 2000, 80: 587-594.
81 King SJ, Heath PJ, Luque I, Tarradas C, Dowson CG, Whatmore AM. Distribution and Genetic Diversity of Suilysin in Streptococcus suis Isolated from Different Diseases of Pigs and Characterization of the Genetic Basis of Suilysin Absence. Infect Immun, 2001,12: 7572-7582.
82 King SJ, Leigh JA, Heath PJ, Luque I, Tarradas C, Dowson CG, Whatmore AM. Development of a Multilocus Sequence Typing Scheme for the Pig Pathogen Streptococcus suis: Identification of Virulent Clones and Potential Capsular Serotype Exchange. J Clin Microbiol, 2002,40:3671-3680.
83 Kiston J, Raven T, Yingping J, et al. A deathdomain-containing receotor that mediates apoptosis. Nature, 1996, 384:372-375.
84 Lalonde M, Segura M, Lacouture S, Gottschalk M. Interactions between Streptococcus suis serotype 2 and different epithelial cell lines. Microbiol, 2000, 146:1913-1921.
85 Lammler, C, and R. Weiss. 1997. Characterisation of an unusual Streptococcus suis isolated from an aborted fetus of a pig. Med. Sci. Res. 25:263-264.
86 Lepperdinger, G, B. Strobl, and G. Kreil. 1998. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J. Biol. Chem. 273:22466-22470.
87 Li, S., S. J. Kelly, E. Lamani, M. Ferraroni, and M. J. Jedrzejas. 2000. Structural analysis of hyaluronan degradation by Streptococcus pneumoniae hyaluronate lyase. EMBO J. 19:1228-1240.
88 Lun S, Perez-Casal J, Connor W, Willson PJ. Role of suilysin in pathogenesis of Streptococcus suis capsular serotype 2. Microbiol Pathogen, 2003, 34:27-37.
89 Lun S, Willson PJ. Expression of green fluorescent protein and its application in pathogenesis studies of serotype 2 Streptococcus suis. J Microbiol Methods, 2004, 56:401-412.
90 Luque, I., C. Tarradas, R. Astorga, A. Perea, H. J. Wisselink, and U. Vecht. 1999. The presence of muramidase released protein and extracellular factor protein in various serotypes of Streptococcus suis isolated from diseased and healthy pigs in Spain. Res. Vet. Sci. 66:69-72.
91 Machines, J. I., and R. Desrosiers. 1999. Agents of the "suiside diseases" of swine Actinobacillus suis, Haemophilus suis, and Streptococcus suis. Can. J.Vet. Res. 63:83-89.
92 Madsen, L. W., B. Svensmark, K. Elvestad, B. Aalbaek, and H. E. Jensen. 2002. Streptococcus suis serotype 2 infection in pigs: new diagnostic and pathogenetic aspects. J. Comp. Pathol. 126:57-65.
93 Mannan AU, Krawen P, Sauter SM, Boehm J, Chronowska A, Paulus W, Neesen J, Engel W. ZFYVE 27 (SPG33) , a Novel Spastin-Binding Protein, Is Mutated in Hereditary Spastic Paraplegia. Am J Hum Genet, 2006, 79: 351-357.
94 Marois C, Bougeard S, Gottschalk M, Kobisch M. Multiplex PCR Assay for Detection of Streptococcus suis Species and Serotypes 2 and 1/2 in Tonsils of Live and Dead Pigs. J Clin Microbiol, 2004, 42: 3169-3175.
95 Marois C, Devendec LL, Gottschalk M, Kobisch M. Molecular characterization of Streptococcus suis strains by 16S-23S intergenic spacer polymerase chain reaction and restriction fragment length polymorphism analysis. Can J Vet Res, 2006, 70:94-104.
96 Martel A, Baele M, Devriese LA, Goossens H, Wisselink HJ, Decostere A, Haesebrouck F. Prevalence and mechanism of resistance against macrolides and lincosamides in Streptococcus suis isolates. Vet Microbiol, 2001, 83:287-297.
97 Martin C. Heidt, Walid Mohamed, et al. Human Infective Endocarditis Caused by Streptococcus suis Serotype 2. J CLINICAL MICROBIOLOGY, Sept. 2005, p. 4898-4901.
98 Martinez G, Harel J, Lacouture S, Gottschalk M. Genetic diversity of Streptococcus suis serotypes 2 and 1/2 isolates recovered from carrier pigs in closed herds. Can J Vet Res, 2002, 66:240-248.
99 McCraith S, Holtzman T, Moss B, fields S. Genome-wide analysis of vaccine virus protein-protein interactions. Proc Natl Acid Sci USA, 2000, 97:4879-4884.
100 Melancon D, Grenier D. Production and Properties of Bacteriocin-Like Inhibitory Substances from the Swine Pathogen Streptococcus suis Serotype 2. App Environ Microbiol, 2003, 69:4482-4488.
101 Melegari M, Scaglionip P, Wands JR. Cloning and characterization of a novel hepatitis B virus X binding protein that inhibits viral replication. J virology, 1998, 72:1737-1743.
102 Morris EJ, Michaud WA, Ji JY, Moon NS, Rocco JW, Dyson NJ. Functional Identification of Api 5 as a Suppressor of E2F-Dependent Apoptosis In Vivo. Plos Genet, 2006, 2:e196.
103 Muller-Alouf H, Carnoy C, Simonet M, Alouf JE. Superantigen bacterial toxins: state of the art. Toxicon, 2001, 39:1691-1701.
104 Murakami Y, Fukazawa H, Kobatake T, Yamagoe S, Takebe Y, Tobiume M, Matsuda M, Uehara Y. A mammalian two-hybrid screening system for inhibitors of interaction between HIV Nef and the cellular tyrosine kinase Hck. Antiviral Res. 2002, 55:161-168.
105 Nizet V, Kim K S, Stins M, Jonas M, Chi E Y, Nguyen D, Rubens C E. Invasion of brain microvascular endothelial cells by group B streptococci. Infect Immun. 1997;65:5074-5081.
106 Norton PM, Rolph C, Ward PN, Bentley RW, Leigh JA. Epithelial invasion and cell lysis by virulent strains of Streptococcus suis is enhanced by the presence of suilysin. FEMS Immunol Med Microbiol, 1999, 26:25-35.
107 Okwumabua O, Abdelmagid O, Chengappa MM. Hybridization analysis of the gene encoding a hemolysin (suilysin) of Streptococcus suis type 2: evidence for the absence of the gene in some isolates. FEMS Microbiol Lett, 1999, 181:113-121.
108 Oliveira S, Batista L, Torremorell M, Pijoan C. Experimental colonization of piglets and gilts with systemic strains of Haemophilus parasuis and Streptococcus suis to prevent disease. Can J Vet Res, 2001, 65: 161-167.
109 Osaki M, Takamatsu D, Shimoji Y, Sekizaki T. Characterization of Streptococcus suis Genes Encoding Proteins Homologous to Sortase of Gram-Positive Bacteria. J Bacteriol, 2002, 184:971-982.
110 Owen RJ. Chromosomal DNA fingerprinting: a new method of species and strain identification applicable to microbial pathogens. J Med Microbiol, 1989, 30:89-99.
111 Page AL, Fromont-Racine M, Sansonetti P, Legrain P, Parsot C. Characterization of the interaction partners of secreted proteins and chaperones of Shigella flexneri. Mol Microbiol, 2001, 42:1133-1145.
112 Pallares FJ, Schmitt CS, Roth JA, Evans RB, Kinyon JM, Halbur PG Evaluation of a ceftiofur-washed whole cell Streptococcus suis bacterin in pigs. Can J Vet Res, 2004, 68:236-240.
113 Pedroli S, Kobisch M, Beauchet O, Chaussinand JP, Lucht F. Streptococcus suis bacteremia. Presse Med, 2003, 32:599-601.
114 Polissi, A., A. Pontiggia, G Feger, M. Altieri, H. Mottl, L. Ferrari, and D. Simon. 1998. Large scale identification of virulence genes from Streptococcus pneumoniae. Infect. Immun. 66:5620-5629.
115 Rai, S. K.., F.-M. Duh, V. Vigdorovich, A. Danilkovitch-Miagkova, M. I.Lerman, and A. D. Miller. 2001. Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc. Natl. Acad. Sci. USA 98:4443-4448.
116 Rasmussen SR, Aarestrup FM, Jensen NE, Jorsal SE. Associations of Streptococcus suis Serotype 2 Ribotype Profiles with Clinical Disease and Antimicrobial Resistance. J Clin Microbiol, 1999, 37: 404-408.
117 Ring A, Weiser J N, Tuomanen E I. Pneumococcal trafficking across the blood-brain barrier. J Clin Investig. 1998;102:347-360.
118 Rolland K, Marois C, Siquier V, Cattier B, Quentin R. Genetic features of Streptococcus agalactiae strains causing severe neonatal infections, as revealed by pulsed-field gel electrophoresis and hylB gene analysis. J Clin Microbiol, 1999, 37:1892-1898.
119 Rosenkranz M, Eisner HA, Sturenburg HJ, Weiller C, Rother J, Sobottka I. Streptococcus suis meningitis and septicemia contracted from a wild boar in Germany. J Neurol, 2003, 250: 869-870.
120 Salles MW, Perez-Casal J, Willson P, Middleton DM. Changes in the leucocyte subpopulations of the palatine tonsillar crypt epithelium of pigs in response to Streptococcus suis type 2 infection. Vet Immunol Immunopathol, 2002, 87:51-63.
121 Sambrook, J. Fritsch, E. F. and Maniatis, T. (1989). "Molecular Cloning: A Laboratory Manual," 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,NY.
122 Sasaki H, Moriyama S, Yukiue H, Kobayashi Y, Nakashima Y, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in non-small cell lung cancer. Lung Cancer, 2001, 34: 53-57.
123 Schlegel L, Grimont F, Grimont PA, Bouvet A. Identification of major streptococcal species by rrn-amplified ribosomal DNA restriction analysis. J Clin Microbiol, 2003, 41:657-666.
124 Segers RP, Kenter T, de Haan LA, Jacobs AA. Characterisation of the gene encoding suilysin from Streptococcus suis and expression in field strains. FEMS Microbiol Lett, 1998, 167:255-61.
125 Segura M A, Cleroux P, Gottschalk M. Streptococcus suis and group B Streptococcus differ in their interactions with murine macrophages. FEMS Immunol Med Microbiol. 1998;21:189-195.
126 Segura M, Gottschalk M, Olivier M. Encapsulated Streptococcus suis inhibits activation of signaling pathways involved in phagocytosis. Infect Immun, 2004b, 72:5322-5330.
127 Segura M, Gottschalk M. Extracellular virulence factors of streptococci associated with animal diseases. Front Biosci, 2004a, 9:1157-1188.
128 Segura M, Gottschalk M. Streptococcus suis interactions with the murine macrophage cell line J774: adhesion and cytotoxicity. Infect Immun, 2002, 70:4312-4322.
129 Segura M, Stankova J, Gottschalk M. Heat-Killed Streptococcus suis Capsular Type 2 Strains Stimulate Tumor Necrosis Factor Alpha and Interleukin-6 Production by Murine Macrophages. Infect Immun, 1999, 67:4646-4654.
130 Sekizaki T, Otani Y, Osaki M, Takamatsu D, Shimoji Y. Evidence for horizontal transfer of SsuDAT1I restriction-modification genes to the Streptococcus suis genome. J Bacteriol, 2001,183:500-511.
131 Shaver YJ, Nagpal ML, Rudner R, Nakamura LK, Fox KF, Fox A. Restriction fragment length polymorphism of rRNA operons for discrimination and intergenic spacer sequences for cataloging of Bacillus subtilis sub-groups. J Microbiol Methods, 2002,50:215-223.
132 Silva LMG, Baums CG, Rehm T, Wisselink HJ, Goethe R, Valentin-Weigand P. Virulence-associated gene profiling of Streptococcus suis isolates by PCR. Vet Microbiol, 2006, 115:117-127.
133 Slater JD, Allen AG, May JP, Bolitho S, Lindsay H, Maskell DJ. Mutagenesis of Streptococcus equi and Streptococcus suis by transposon Tn917. Vet Microbiol, 2003, 93:197-206.
134 Smith HE, Buijs H, de Vries R, Wisselink HJ, Stockhofe-Zurwieden N, Smits MA. Environmentally regulated genes of Streptococcus suis: identification by the use of iron-restricted conditions in vitro and by experimental infection of piglets. Microbiol 2001; 147: 271-80.
135 Smith HE, Buijs H, Wisselink HJ, Stockhofe-Zurwieden N, Smits MA. Selection of Virulence-Associated Determinants of Streptococcus suis Serotype 2 by In Vivo Complementation. Infect Immun, 2001, 69: 1961-1966.
136 Smith HE, Damman M, van der Velde J, Wagenaar F, Wisselind HJ, Stockhofe-zurwieden N, Smits MA. Identification and Characterization of the cps Locus of Streptococcus suis Serotype 2: the Capsule Protects against Phagocytosis and Is an Important Virulence Factor. Infect Immun, 1999, 67: 1750-1756.
137 Sorensen NS, Tegtmeier Ca, Andresen LO, Pineiro M, Toussaint MJM, Campbell FM, Lampreave F, Heegaard PMH. The porcine acute phase protein response to acute clinical and subclinical experimental infection with Streptococcus suis. Vet Immunol Immunopathol, 2006, 113:157-168.
138 Sprenger H, Rosier A, Tonn P, Braune HJ, Huffmann G, Gemsa D. Chemokines in the cerebrospinal fluid of patients with meningitis. Clin Immunol Immunopathol, 1996, 80:155-161.
139 Sriskandan S, Slater JD. Invasive Disease and Toxic Shock due to Zoonotic Streptococcus suis: An Emerging Infection in the East?. Plos Med, 2006, 3:e187.
140 Staats JJ, Feder I, Okwumabua O, Chengappa MM. Streptococcus suis: past and present. Vet Res Commun, 1997,21:381-407.
141 Staats JJ, Plattner BL, Nietfeld J, Dritz S, Chengappa MM. Use of ribotyping and hemolysin activity to identify highly virulent Streptococcus suis type 2 isolates. J Clin Microbiol, 1998, 36:15-19.
142 Stein E, Huynh-Do U, Daniel TO. Nck recruitment to Eph receptor, EphBl/ELK, couples ligand activation to c-Jun kinase. J Biol Chem, 1998, 273:1303-1308.
143 Stenmark H, Aasland R. FYVE-finger proteins-effectors of an inositol lipid. J Cell Sci, 1999,112:4175-4183.
144 Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst) , 2004, 3: 1071-1079.
145 Strangmann E, Froleke H, Kohse KP. Septic shock caused by Streptococcus suis: Case report and investigation of a risk group. Int J Hyg Environ Health, 2002, 205:385-392.
146 Takamatsu D, Osaki M, Sekizaki T. Evidence for Lateral Transfer of the Suilysin Gene Region of Streptococcus suis. J Bacterial, 2002, 184: 2050-2057.
147 Takamatsu D, Osaki M, Sekizaki T. Thermosensitive suicide vectors for gene replacement in Streptococcus suis. Plasmid. 2001 Sep;46(2): 140-8
148 Takamatsu, D., Osaki, M., and Sekizaki, T. (2001). Construction and characterization of Streptococcus suis-Escherichia coli shuttle cloning vectors. Plasmid 45, 101-113, doi:10.1006/plas.2000.1510.
149 Takamatsu, D., Osaki, M., and Sekizaki, T. (2001). Construction and characterization of Streptococcus suis-Escherichia coli shuttle cloning vectors. Plasmid 45, 101-113, doi:10.1006/plas.2000.1510.
150 Tang J, Wang C, Feng Y, Yang W, Song H, Chen Z, Yu H, Pan X, Zhou X, Wang H, Wu B, Wang H, Zhao H, Lin Y, Yue J, Wu Z, He X, Gao F, Khan AH, Wang J, Zhao G, Wang Y, Wang X, Chen Z, Gao GF. Streptococcal toxic shock syndrome caused by Streptococcus suis serotype 2. PLoS Med, 2006, 3:e151.
151 Tarradas C, Borge C, Arenas A, Maldonado A, Astorga R, Miranda A, Luque I. Suilysin production by Streptococcus suis isolated from diseased and healthy carrier pigs in Spain. Vet Rec, 2001, 148:183-184.
152 Tarradas C, Luque I, de Andres D, Abdel-Aziz Shahein Ye, Pons P, Gonzalez F, Borge C, Perea A. Epidemiological relationship of human and swine Streptococcus suis isolates. J Vet Med B Infect Dis Vet Public Health, 2001, 48:347-355.
153 Tettelin H, Masignani V, et al.Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A. 2005 Sep 27; 102(39): 13950-5
154 Tewari M, Yu M, Ross B, Dean C, Giordano A, Rubin R. AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal. Cancer Res, 1997, 57: 4063-4069.
155 Thompson C, Merrilf AR, Mangroo D. Identification of peptide inhibitors of Pseudomonas aeruginosa exotoxin A function using a yeast two-hybrid approach. FEMS Microbiol Lett, 2003, 218:85-92.
156 Ton-That H, Liu G, Mazmanian SK, Faull KF, Schneewind O. Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif. Proc Natl Acad Sci USA, 1999, 96:12424-12429.
157 Ton-That H, Mazmanian SK, Faull KF, Schneewind O. Anchoring of surface proteins to the cell wall of Staphylococcus aureus Sortase-catalyzed in vitro transpeptidation reaction using LPXTG peptide and NH2-Gly3 substrates. J Biol Chem, 2000, 275:9876-9881.
158 Torremorell M, Pijoan C. Prolonged persistence of an epidemic Streptococcus suis strain in a closed pig population. Vet Rec, 1998, 143:394-395.
159 Uetz P, Giot L, Cagney G, Mansfield TA, Judson RS, Knight JR, Lockshon D, Narayan V, Srinivasan M, Pochart P, Qureshui-Emili A, Li Y, Godwin B, Conover D, Kalbfleisch T, Vijayadamodar G, Yang M, Johnston M, Fields S, Rothberg JM. A comprehensive analysis of protien-protein interactions in Saccharomyces cerevisiae. Nature, 2000,403: 623-627.
160 Vanier G, Segura M, Fried P, Lacouture S, Gottschalk M. Invasion of Porcine Brain Microvascular Endothelial Cells by Streptococcus suis Serotype 2. Infect Immun, 2004, 72:1441-1449.
161 Vela AI, Goyache J, Tarradas C, Luque I, Mateos A, Moreno MA, Borge C, Perea JA, Dominguez L, Fernandez-Garayzabal JF. Analysis of genetic diversity of Streptococcus suis clinical isolates from pigs in Spain by pulsed-field gel electrophoresis. J Clin Microbiol, 2003, 41:2498-2502.
162 Verheijen R, Osswald IK, Dietrich R, Haasnoot W, Development of a One Step Strip Test for the Detection of (Dihydro) streptomycin Residues in Raw Milk. Food Agricul Immunol, 2000, 12:31-40
163 Victor J. Torres, Mark S, McClain, Timothy L. Cover. Interactions between p-33 and p-55 domains of the Helicobacter pylori Vacuolating Cytotoxin (VacA). J Biol Chem, 2004,279:2324-2331.
164 Wake, R. D., D. W. Penfold, J. K. Struthers, and C. G Dowson. 2003. Spontaneous sequence duplications within capsule genes cap8E and tts control phase variation in Streptococcus pneumoniae serotypes 8 and 37. Microbiology 149:497-504.
165 Waite, R. D., J. K. Struthers, and C. G Dowson. 2001. Spontaneous sequence duplication within an open reading frame of the pneumococcal type 3 capsule locus causes high-frequency phase variation. Mol. Microbiol. 42: 1223-1232.
166 Walhot AJ, Sordella R, Lu X, et al. Protein interaction mapping in C. elegans using protein involved in vulval development. Science, 2000,287:116-122.
167 Wang YH, Dong DP, Xie Q, Wang DX, Han LZ, Ni YX. Analysis of infectious syndrome caused by Streptococcus suis type 2. Jiangsu Med J 2005; 31: 419-20 (in Chinese).
168 Wen HW, Borejsza-Wysocki W, Thomas R. DeCory TR, Durst RA. Development of a competitive liposome-based lateral flow assay for the rapid detection of the allergenic peanut protein Ara h1. Anal Bioanal Chem, 2005, 382: 1217-1226.
169 Whatmore, A. M., V. A. Barcus, and C. G Dowson. 1999. Genetic diversity of the streptococcal competence (com) gene locus. J. Bacteriol. 181:3144-3154.
170 Wilson TL, Jeffers J, Rapp-Gabrielson VJ, Martin S, Klein LK, Lowery DE, Fuller TE. A novel signature-tagged mutagenesis system for Streptococcus suis serotype 2.Vet Microbiol, 2007, doi:10.1016/j.vetmic.2006.12.025.
171 Wisselink HJ, Reek FH, Vecht U, Stockhofe-Zurwieden N, Smits MA, Smith HE. Detection of virulent strains of Streptococcus suis type 2 and highly virulent strains of Streptococcus suis type 1 in tonsillar specimens of pigs by PCR. Vet Microbiol, 1999,67:143-157.
172 Wisselink HJ, Smith HE, Stockhofe-Zurwieden N, Peperkamp K, Vecht U. Distribution of capsular types and production of muramidase-released protein (MRP) and extracellular factor (EF) of Streptococcus suis strains isolated from diseased pigs in seven European countries. Vet Microbiol, 2000, 74:237-248.
173 Wisselink HJ, Stockhofe-Zurwieden N, Hilgers L, Smith HE. Assessment of protective efficacy of live and killed vaccines based on a non-encapsulated mutant of Streptococcus suis type 2. Vet Microbiol, 2002, 84:155-168.
174 Wisselink HJ, Vecht U, Stockhofe-Zurwieden N, Smith HE. Protection of pigs against challenge with virulent Streptococcus suis serotype 2 strains by a muramidase-released protein and extracellular factor vaccine.Vet Rec,2001,148:473-477.
175 Wisselink H J,Veldman KT,Van den Eede C,Salmon SA,Mevius DJ.Quantitative susceptibility of Streptococcus suis strains isolated from diseased pigs in seven European countries to antimicrobial agents licensed in veterinary medicine.Vet Microbiol,2006,113:73-82.
176 Yang JX,Jin ML,Chen JF,Yang Y,Zheng P,Zhang AD,Song YF,Zhou HB,Chen HC.Development and evaluation of an immunochromatographic strip for detection of Streptococcus suis type 2 antibody.J Vet Diagn Invest,2007,19(in press)
177 Yu H,Jing H,Chen Z,Zheng H,Zhu X,Wang H,Wang S,Liu L,Zu R,Luo L,Xiang N,Liu H,Liu X,Shu Y,Lee S,Chuang S,Wang Y,Xu J,Yang W,China SSG.Human Streptococcus suis outbreak,Sichuan,China.Emerg Infect Dis,2006,12:914-920.
178 Zhao-Rong Lun,Qiao-Ping Wang,Xiao-Guang Chen,An-Xing Li,Xing-Quan Zhu,Streptococcus suis:an emerging zoonotic pathogen,J,Lancet Infect Dis 2007;7:201-09
179 Zwijnenburg,P.J.,T.van der Poll,S.Florquin,S.J.van Deventer,J.J.Roord,and A.M.van Furth.2001.Experimental pneumococcal meningitis in mice:a model of intranasal infection.J.Infect.Dis.183:1143-1146.
